Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2

被引:279
|
作者
Amary, M. Fernanda [1 ]
Damato, Stephen [1 ]
Halai, Dina [1 ]
Eskandarpour, Malihe [2 ]
Berisha, Fitim [1 ]
Bonar, Fiona [3 ]
McCarthy, Stan [4 ]
Fantin, Valeria R. [5 ]
Straley, Kimberly S. [5 ]
Lobo, Samira [1 ]
Aston, Will [6 ]
Green, Claire L. [2 ]
Gale, Rosemary E. [2 ]
Tirabosco, Roberto [1 ]
Futreal, Andrew [7 ]
Campbell, Peter [7 ]
Presneau, Nadege [2 ]
Flanagan, Adrienne M. [1 ,2 ]
机构
[1] Royal Natl Orthopaed Hosp Natl Hlth Serv Trust, Histopathol Unit, Stanmore, Middx, England
[2] Univ Coll London Canc Inst, London, England
[3] Douglass Hanly Moir Pathol, Sydney, NSW, Australia
[4] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia
[5] Agios Pharmaceut, Cambridge, MA USA
[6] Royal Natl Orthopaed Hosp Natl Hlth Serv Trust, Bone Tumour Unit, Stanmore, Middx, England
[7] Wellcome Trust Sanger Inst, Cambridge, England
基金
英国惠康基金;
关键词
ENCHONDROMATOSIS; GLIOMA;
D O I
10.1038/ng.994
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Ollier disease and Maffucci syndrome are characterized by multiple central cartilaginous tumors that are accompanied by soft tissue hemangiomas in Maffucci syndrome. We show that in 37 of 40 individuals with these syndromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of which result in a R132C substitution in the protein. In 18 of 19 individuals with more than one tumor analyzed, all tumors from a given individual shared the same IDH1 mutation affecting Arg132. In 2 of 12 subjects, a low level of mutated DNA was identified in non-neoplastic tissue. The levels of the metabolite 2HG were measured in a series of central cartilaginous and vascular tumors, including samples from syndromic and nonsyndromic subjects, and these levels correlated strongly with the presence of IDH1 mutations. The findings are compatible with a model in which IDH1 or IDH2 mutations represent early post-zygotic occurrences in individuals with these syndromes.
引用
收藏
页码:1262 / U129
页数:5
相关论文
共 50 条
  • [41] IDH1/2 mutation detection in gliomas
    Hideyuki Arita
    Yoshitaka Narita
    Akihiko Yoshida
    Naoya Hashimoto
    Toshiki Yoshimine
    Koichi Ichimura
    Brain Tumor Pathology, 2015, 32 : 79 - 89
  • [42] Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis
    Phan, Kevin
    Ng, Wyatt
    Lu, Victor M.
    McDonald, Kerrie L.
    Fairhall, Jacob
    Reddy, Rajesh
    Wilson, Peter
    WORLD NEUROSURGERY, 2018, 111 : E539 - E545
  • [43] Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas
    Arita, Hideyuki
    Narita, Yoshitaka
    Matsushita, Yuko
    Fukushima, Shintaro
    Yoshida, Akihiko
    Takami, Hirokazu
    Miyakita, Yasuji
    Ohno, Makoto
    Shibui, Soichiro
    Ichimura, Koichi
    BRAIN TUMOR PATHOLOGY, 2015, 32 (01) : 22 - 30
  • [44] IDH1 Non-Canonical Mutations and Survival in Patients with Glioma
    Franceschi, Enrico
    De Biase, Dario
    Di Nunno, Vincenzo
    Pession, Annalisa
    Tosoni, Alicia
    Gatto, Lidia
    Tallini, Giovanni
    Visani, Michela
    Lodi, Raffaele
    Bartolini, Stefania
    Brandes, Alba Ariela
    DIAGNOSTICS, 2021, 11 (02)
  • [45] IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?
    Labussiere, Marianne
    Sanson, Marc
    Idbaih, Ahmed
    Delattre, Jean-Yves
    ONCOLOGIST, 2010, 15 (02) : 196 - 199
  • [46] Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas
    Hideyuki Arita
    Yoshitaka Narita
    Yuko Matsushita
    Shintaro Fukushima
    Akihiko Yoshida
    Hirokazu Takami
    Yasuji Miyakita
    Makoto Ohno
    Soichiro Shibui
    Koichi Ichimura
    Brain Tumor Pathology, 2015, 32 : 22 - 30
  • [47] Differentiation therapy for IDH1/2 mutant malignancies
    Garrett-Bakelman, Francine E.
    Melnick, Ari M.
    CELL RESEARCH, 2013, 23 (08) : 975 - 977
  • [48] A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database
    Pappula, Amrit L.
    Rasheed, Shayaan
    Mirzaei, Golrokh
    Petreaca, Ruben C.
    Bouley, Renee A.
    CANCERS, 2021, 13 (17)
  • [49] Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma
    Zhu, Guo Gord
    Nafa, Khedoudja
    Agaram, Narasimhan
    Zehir, Ahmet
    Benayed, Ryma
    Sadowska, Justyna
    Borsu, Laetitia
    Kelly, Ciara
    Tap, William D.
    Fabbri, Nicola
    Athanasian, Edward
    Boland, Patrick J.
    Healey, John H.
    Berger, Michael F.
    Ladanyi, Marc
    Hameed, Meera
    CLINICAL CANCER RESEARCH, 2020, 26 (02) : 419 - 427
  • [50] IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
    Zhang, Chunzhi
    Moore, Lynette M.
    Li, Xia
    Yung, W. K. Alfred
    Zhang, Wei
    NEURO-ONCOLOGY, 2013, 15 (09) : 1114 - 1126